Patanol Pharmacology, Pharmacokinetics, Studies, Metabolism - Olopatadine

Patanol Pharmacology, Pharmacokinetics, Studies, Metabolism - Olopatadine

CLINICAL PHARMACOLOGY

Olopatadine is an inhibitor of the release of histamine from the mast cell and a relatively selective histamine H₁ –antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells. Olopatadine is devoid of effects on alpha-adrenergic,dopamine and muscarinic type 1 and 2 receptors.Following topical ocular administration in man,olopatadine was shown to have low systemic exposure. Two studies in normal volunteers (totaling 24 subjects) dosed bilaterally with olopatadine 0.15% ophthalmic solution once every 12 hours for 2 weeks demonstrated plasma concentrations to be generally below the quantitation limit of the assay (<0.5 ng/mL). Samples in which olopatadine was quantifiable were typically found within 2 hours of dosing and ranged from 0.5 to 1.3 ng/mL. The half-life in plasma was approximately 3 hours,and elimination was predominantly through renal excretion. Approximately 60-70% of the dose was recovered in the urine as parent drug. Two metabolites,the mono-desmethyl and the N-oxide,were detected at low concentrations in the urine.

Results from an environmental study demonstrated that PATANOL was effective in the treatment of the signs and symptoms of allergic conjunctivitis when dosed twice daily for up to 6 weeks. Results from conjunctival antigen challenge studies demonstrated that PATANOL,when subjects were challenged with antigen both initially and up to 8 hours after dosing,was significantly more effective than its vehicle in preventing ocular itching associated with allergic conjunctivitis.